Phase 2 Breast Cancer Trial, Recruiting NCT05918328 Sponsor: Henan Cancer Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT05918328
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 to 65 years old who are generally able to carry out normal daily activities with little or no limitation (confirm with trial site regarding the activity level scale used)
  • People whose breast cancer has been assessed as a certain size or spread within the breast or nearby lymph nodes (clinical stage T2–T4d, or T1c with positive armpit lymph nodes)
  • People with HER2-positive invasive breast cancer, confirmed by laboratory testing of breast tissue
  • People who have at least one tumour that can be measured by ultrasound, mammogram, or MRI within one month before joining the trial
  • People whose blood counts and organ function (including neutrophils, haemoglobin, platelets, liver function, and kidney function) fall within acceptable ranges within one month before starting chemotherapy
  • People whose heart is pumping well enough, with a left ventricular ejection fraction (a measure of heart pumping strength) of 55% or above on a heart ultrasound
  • Women who could become pregnant must have a negative blood pregnancy test taken within 14 days before joining
  • People who have read and signed the trial's informed consent form

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose breast cancer has spread to other parts of the body (stage IV/metastatic)
  • People who have already received chemotherapy, hormone therapy, targeted therapy, or radiation therapy for this breast cancer
  • People who have a second, separate cancer diagnosis, unless it is a skin cancer that has been fully treated
  • People who have had a major surgery unrelated to breast cancer within 4 weeks before enrolling, or who have not fully recovered from such a surgery
  • People with serious heart conditions, including a history of heart failure, uncontrolled irregular heart rhythms, resting heart rate above 100 beats per minute, significant heart valve disease, evidence of a previous heart attack on an ECG, chest pain requiring medication, or poorly controlled high blood pressure (above 180/100 mmHg)
  • People with other serious, uncontrolled medical conditions that the trial doctors believe would make chemotherapy unsafe
  • People with a known allergy to any of the trial medications, a history of immune system deficiency (including a positive HIV test), any other inherited or acquired immune deficiency condition, or a history of organ transplantation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

Contact this trial

Principal Investigator: Zhenzhen Liu, Study Principal Investigator

Phone: 13603862755

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Henan Cancer Hospital
Registry
ClinicalTrials.gov
Start date
3 May 2023
Est. completion
1 December 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological complete response rate (pCR rate)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov